Elvitegravir is an experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. integrase inhibitor currently in phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. clinical trials.
Like raltegravir (the only drug in this class approved for use in Australia) elvitegravir will be of most use to people with multiple drug reisistance.
Integrase inhibitors target an enzyme called integrase which HIV uses to integrate its genetic code into human cells. Because this is a different point of action to that targeted by other drug classes, there is a good chance that people who have failed several prior treatment regimens will benefit from this drug, especially if it is combined with an optimised background regimen.
According to the results of phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trials, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate..
UPDATE March 2011
Elvitegravir appears to be working well in a Phase III clinical trial involving treatment-experienced patients, according to a March 23 press release by Gilead, the company who manufactures the drug. Though the study will last about two years (96 weeks), Gilead says the study’s primary goal has been met: comparable results between patients receiving either elvitegravir or Merck’s approved integrase inhibitor Isentress (raltegravir) for 48 weeks
| Generic name: |
elvitegravir (EVG) |
|---|
| Pronunciation: | el-vy-TEG-ra-veer |
|---|
| Also known as: | GS-9137, JTK-303 |
|---|
| Drug class: | integrase inhibitor |
|---|
| Availability in Australia: | - Not available on the Pharmaceutical Benefits Scheme (PBS).
- This drug may be available through clinical trials in Australia.
- You may be able to import this drug from overseas for your personal use.
|
|---|
| Links: | |
|---|
Like most anti-HIV drugs, elvitegravir must be taken in combination with other drugs to be completely effective. Your doctor will advise you on the right combination of drugs to suit your circumstances.
Dosage
150mg once daily combined with 100mg ritonavir.
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
Side effects
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
Interactions with other drugs
Studies on potential interactions between elvitegravir and other drugs have not yet been reported, but are planned and ongoing.
Adrian Ogier gives the low-down on latest antiretroviralA medication or other substance which is active against retroviruses such as HIV. treatments. read more »
The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia. read more »
A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years. read more »
The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story. read more »
The table below shows all the clinical trials in the database with the keyword elvitegravir (GS-9137).
This site complies with the HONcode standard for trustworthy health information: verify here. 
